Shares of Medivation Inc. (NASDAQ:MDVN) were down 0.4% during mid-day trading on Friday . The company traded as low as $62.32 and last traded at $62.51, with a volume of 472,217 shares changing hands. The stock had previously closed at $62.74.

A number of analysts have recently issued reports on MDVN shares. Goldman Sachs Group Inc. started coverage on shares of Medivation in a report on Wednesday, March 30th. They issued a “neutral” rating and a $44.00 price objective on the stock. Leerink Swann reissued a “hold” rating and issued a $70.00 target price (up from $55.00) on shares of Medivation in a research note on Monday, April 25th. Canaccord Genuity reissued a “hold” rating and issued a $45.00 target price on shares of Medivation in a research note on Tuesday, March 29th. Credit Suisse Group AG reissued an “outperform” rating and issued a $63.00 target price on shares of Medivation in a research note on Wednesday. Finally, Jefferies Group reissued a “hold” rating and issued a $56.00 target price on shares of Medivation in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $71.76.

The company has a 50 day moving average of $60.11 and a 200-day moving average of $47.22. The company has a market cap of $10.22 billion and a price-to-earnings ratio of 41.71.

Medivation (NASDAQ:MDVN) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.23 by $0.12. The firm earned $182.50 million during the quarter, compared to analysts’ expectations of $197.01 million. During the same quarter last year, the firm posted $0.17 EPS. The business’s revenue for the quarter was up 41.3% on a year-over-year basis. On average, analysts anticipate that Medivation Inc. will post $1.31 EPS for the current fiscal year.

In other news, SVP Andrew Kenneth William Powell sold 2,578 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $60.42, for a total value of $155,762.76. Following the sale, the senior vice president now directly owns 28,517 shares in the company, valued at $1,722,997.14. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Rick Bierly sold 10,340 shares of the stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $59.76, for a total value of $617,918.40. Following the completion of the sale, the chief financial officer now owns 35,059 shares in the company, valued at $2,095,125.84. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. increased its position in Medivation by 16.6% in the fourth quarter. Advisors Asset Management Inc. now owns 25,952 shares of the biopharmaceutical company’s stock valued at $1,255,000 after buying an additional 3,688 shares during the last quarter. TD Asset Management Inc. increased its position in Medivation by 9.5% in the fourth quarter. TD Asset Management Inc. now owns 28,804 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 2,500 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. increased its position in Medivation by 7.2% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 29,559 shares of the biopharmaceutical company’s stock valued at $1,429,000 after buying an additional 1,979 shares during the last quarter. Andra AP fonden increased its position in Medivation by 19.5% in the fourth quarter. Andra AP fonden now owns 30,600 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 5,000 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new position in Medivation during the fourth quarter valued at approximately $1,710,000.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.